US2009181456A1PendingUtilityA1

Adipose-derived stem cells and lattices

63
Individually held — no corporate assignee on recordPriority: Mar 10, 1999Filed: Dec 8, 2008Published: Jul 16, 2009
Est. expiryMar 10, 2019(expired)· nominal 20-yr term from priority
Inventors:Marc H. HedrickAdam J. KatzRamon LluilJ. William FutrellProsper BenhaimHermann Peter LorenzMin Zhu
C12N 5/0068C12N 2500/42A61K 48/00C12N 2533/90C12N 2501/15C12N 2500/38C12N 2501/39C12N 2501/01C12N 2510/00C12N 2500/25C12N 5/0667A61K 35/12C12N 2501/33C12N 5/0662
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides adipose-derived stem cells (ADSCs), adipose-derived stem cell-enriched fractions (ADSC-EF) and adipose-derived lattices, alone and combined with the ADSCs of the invention. In one aspect, the present invention provides an ADSC substantially free of adipocytes and red blood cells and clonal populations of connective tissue stem cells. The ADSCs can be employed, alone or within biologically-compatible compositions, to generate differentiated tissues and structures, both in vivo and in vitro. Additionally, the ADSCs can be expanded and cultured to produce molecules such as hormones, and to provide conditioned culture media for supporting the growth and expansion of other cell populations. In another aspect the present invention provides a adipose-derived lattice substantially devoid of cells, which includes extracellular matrix material from adipose tissue. The lattice can be used as a substrate to facilitate the growth and differentiation of cells, whether in vivo or in vitro, into anlagen or even mature tissues or structures.

Claims

exact text as granted — not AI-modified
1 . (canceled) 
     
     
         2 . (canceled) 
     
     
         3 . (canceled) 
     
     
         4 . (canceled) 
     
     
         5 . (canceled) 
     
     
         6 . (canceled) 
     
     
         7 . (canceled) 
     
     
         8 . (canceled) 
     
     
         9 . (canceled) 
     
     
         10 . (canceled) 
     
     
         11 . (canceled) 
     
     
         12 . (canceled) 
     
     
         13 . (canceled) 
     
     
         14 . (canceled) 
     
     
         15 . (canceled) 
     
     
         16 . (canceled) 
     
     
         17 . (canceled) 
     
     
         18 . (canceled) 
     
     
         19 . (canceled) 
     
     
         20 . (canceled) 
     
     
         21 . (canceled) 
     
     
         22 . (canceled) 
     
     
         23 . (canceled) 
     
     
         24 . (canceled) 
     
     
         25 . (canceled) 
     
     
         26 . (canceled) 
     
     
         27 . (canceled) 
     
     
         28 . (canceled) 
     
     
         29 . (canceled) 
     
     
         30 . (canceled) 
     
     
         31 . (canceled) 
     
     
         32 . (canceled) 
     
     
         33 . (canceled) 
     
     
         34 . (canceled) 
     
     
         35 . (canceled) 
     
     
         36 . (canceled) 
     
     
         37 . (canceled) 
     
     
         38 . A method of conditioning culture medium comprising exposing a cell culture medium to an isolated population of stem cells obtained from human adipose tissue, under conditions sufficient for the cell to condition the medium, wherein the isolated population of stem cells obtained from human adipose tissue has a CD marker profile comprising:
 (i) a combination of STRO-1+, CD29+, CD44+, CD71+, CD49D+, CD90+, and CD105+;   (ii) STRO-1, CD49d, low or undetectable levels of CD106, any one or more of CD29, CD44, CD71, CD90, SH3, and CD105, and CD31−, and CD45−; or   (iii) a combination of STRO-1+, CD29+, CD44+, CD49D+, CD71+, CD90+, CD1 05+, CD31−, and CD45−.   
     
     
         39 . (canceled) 
     
     
         40 . (canceled) 
     
     
         41 . (canceled) 
     
     
         42 . (canceled) 
     
     
         43 . (canceled) 
     
     
         44 . The method of  claim 38 , wherein the medium is separated from the cell after it has been conditioned. 
     
     
         45 . A conditioned culture medium produced in accordance with the method of  claim 44 . 
     
     
         46 . The conditioned culture medium of  claim 45 , which is substantially free of the stem cells. 
     
     
         47 . A method of culturing a stem cell comprising maintaining a stem cell in the conditioned medium of  claim 46  under conditions for the stem cell to remain viable. 
     
     
         48 . The method of  claim 47 , which further comprises permitting successive rounds of mitotic division of the stem cell to form an expanded population of stem cells. 
     
     
         49 . The method of  claim 47 , wherein the medium is substantially free of the stem cells. 
     
     
         50 . The method of  claim 47 , wherein the medium contains the stem cells. 
     
     
         51 . The method of  claim 48 , wherein a stem cell is a hematopoetic stem cell. 
     
     
         52 . A method of differentiating an isolated population of stem cells obtained from human adipose tissue, comprising culturing the cell in media comprising the conditioned culture medium of  claim 45  under conditions sufficient for the cell to differentiate, wherein the isolated population of stem cells obtained from human adipose tissue has a CD marker profile comprising:
 a. a combination of STRO-1+, CD29+, CD44+, CD71+, CD49D+, CD90+, and CD105+;   b. STRO-1, CD49d, low or undetectable levels of CD106, any one or more of CD29, CD44, CD71, CD90, SH3, and CD105, and CD31−, and CD45−; or   c. a combination of STRO-1+, CD29+, CD44+, CD49D+, CD71+, CD90+, CD105+, CD31−, and CD45−.   
     
     
         53 . The method of  claim 52 , wherein the cell differentiates in vitro. 
     
     
         54 . The method of  claim 52 , wherein the cell differentiates in vivo.

Join the waitlist — get patent alerts

Track US2009181456A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.